From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Are we maintaining minimal residual disease in myeloma?

Last Updated: Wednesday, January 22, 2025

Minimal residual disease (MRD) is a key prognostic marker in multiple myeloma. This review examines the role of MRD testing, particularly during maintenance therapy, and its potential to inform clinical decisions. MRD's utility and dynamics are also examined.

 

Leukemia & Lymphoma
Advertisement
News & Literature Highlights
Advertisement
Advertisement